Beyond the non‐CDN small‐molecule STING agonists discussed above, which exhibit favorable drug‐like properties and enhanced cytosolic delivery compared to the anionic and highly water‐soluble CDNs, alternative STING activators have also been identified for their potential in tumor immunotherapy. The gene discussed is STING1; the disease is neoplasm.